NFKB1 (Ab-907) Antibody

What is NFKB1 and why is it important for immunological research?

NFKB1 (Nuclear Factor Kappa B Subunit 1) is a protein-coding gene that encodes two distinct protein forms: p105 (105 kD precursor) and p50 (50 kD processed form). The p105 protein functions as a Rel protein-specific transcription inhibitor, while p50 serves as a DNA binding subunit of the NF-kappa-B (NF-κB) protein complex. This pathway represents a master regulatory system for immune and inflammatory responses in virtually all cell types . NFKB1 plays crucial roles in mediating cellular responses to diverse stimuli including cytokines, free radicals, ultraviolet irradiation, and bacterial or viral products, subsequently controlling the expression of genes involved in immunity, inflammation, cell survival, and proliferation .

The significance of NFKB1 in immunological research stems from its central role in integrating multiple stress and inflammatory signals. Activated NFKB1-containing complexes translocate to the nucleus where they bind DNA at κB sites (consensus sequence: 5'-GGRNNYYCC-3'), regulating target gene expression . Importantly, NF-κB dysregulation has been directly linked to various pathological conditions including immunodeficiency disorders, inflammatory diseases, and cancer, making NFKB1 detection and functional characterization essential for understanding disease mechanisms .

What protein forms does NFKB1 (Ab-907) Antibody typically detect?

NFKB1 (Ab-907) Antibody is designed to recognize both major forms of the NFKB1 protein, providing comprehensive pathway analysis capabilities. This antibody detects:

• p105 (105 kD): The full-length precursor form that contains an N-terminal Rel homology domain (RHD) and C-terminal ankyrin repeats. This precursor functions as a cytoplasmic retention factor for various NF-κB proteins, effectively acting as an IκB-like protein that regulates NF-κB activation .

• p50 (50 kD): The processed form generated through cotranslational or post-translational processing of p105 by the 26S proteasome. p50 contains the RHD domain and functions as the DNA-binding subunit that can form both homodimers (typically repressive) and heterodimers with RelA/p65 (typically activating) .

The ability of Ab-907 to detect both forms simultaneously makes it particularly valuable for studying processing dynamics between p105 and p50, a key regulatory mechanism in NF-κB signaling. When performing western blotting with this antibody, researchers should expect to observe two distinct bands corresponding to these protein forms, with their relative intensities providing information about pathway activation states .

How can I verify the specificity of NFKB1 (Ab-907) Antibody in my experimental system?

Verifying antibody specificity is essential for reliable experimental outcomes. For NFKB1 (Ab-907) Antibody, implement these systematic validation approaches:

• Genetic validation: Compare wild-type cells with NFKB1 knockout or knockdown models. In true knockout systems, both p105 and p50 bands should be absent or dramatically reduced in western blots. Recent studies have identified multiple NFKB1 mutations in human patients with immunodeficiency, which can serve as additional reference samples .

• Peptide competition assay: Pre-incubate the antibody with its immunizing peptide before application to samples. Signal disappearance confirms specificity for the target epitope. This approach is particularly valuable when alternative genetic models are unavailable.

• Stimulus response testing: Treat cells with established NF-κB activators such as TNFα, LPS, or IL-1β. Expect increased nuclear p50 levels and possible changes in p105/p50 ratio. NFKB1 gene expression itself is regulated by NF-κB pathway activation, showing upregulation in control cells but deficient response in some mutant cells .

• Cross-validation with other antibodies: Compare detection patterns with other validated NFKB1 antibodies targeting different epitopes. Consistent band patterns across multiple antibodies support specificity claims .

• Size verification: In western blots, confirm detection of bands at the expected molecular weights (105 kD for p105, 50 kD for p50). Expression of these proteins appears significantly reduced in cells carrying NFKB1 mutations, making these samples valuable negative controls .

How can NFKB1 (Ab-907) Antibody be used to distinguish between active and inactive NF-κB signaling?

Distinguishing between active and inactive NF-κB signaling states requires a multi-parameter approach leveraging the ability of NFKB1 (Ab-907) Antibody to detect both p105 and p50 forms:

• Subcellular fractionation analysis: In inactive NF-κB signaling, p50 predominantly localizes to the cytoplasm, while activation drives nuclear translocation. Quantify the nuclear/cytoplasmic ratio of p50 using clean fractionation protocols followed by western blotting with Ab-907. Lamin B1 and GAPDH serve as nuclear and cytoplasmic markers, respectively, to confirm fraction purity .

• Processing dynamics assessment: Analyze the p105/p50 ratio in total cell lysates. Enhanced p105 processing to p50, reflected by decreased p105:p50 ratio, frequently indicates pathway activation. Experimental evidence shows that disease-associated NFKB1 mutations can disrupt this processing, leading to decreased p50 generation .

• Protein complex characterization: Use NFKB1 (Ab-907) for immunoprecipitation followed by detection of interaction partners. In inactive states, p50 associates with inhibitory proteins, while activation promotes association with transcriptional coactivators and RelA/p65. Research has demonstrated that p50 homodimers typically function as transcriptional repressors, while p50-RelA heterodimers activate gene expression .

• Target gene expression profiling: Couple protein analysis with qPCR measurement of NF-κB target genes. Studies show that lipopolysaccharide (LPS) stimulation induces different target gene expression patterns in wild-type versus NFKB1 mutant cells, with deficient induction of multiple NF-κB targets in mutant cells .

• Chromatin occupancy assessment: Perform ChIP using NFKB1 (Ab-907) to detect p50 binding to κB consensus sequences in gene promoters. Active signaling increases p50 occupancy at target genes, although the functional outcome (activation or repression) depends on dimer composition .

What are the optimal protocols for using NFKB1 (Ab-907) Antibody in chromatin immunoprecipitation (ChIP) experiments?

Optimizing ChIP protocols with NFKB1 (Ab-907) Antibody requires careful consideration of multiple parameters to detect p50 binding to DNA:

• Cell preparation and crosslinking:

  • Stimulate cells with appropriate NF-κB activators (e.g., TNFα for 30 minutes) to enhance p50 DNA binding

  • Use 1% formaldehyde for 10 minutes at room temperature for crosslinking (time may require optimization for specific cell types)

  • Quench with 0.125M glycine for 5 minutes

  • For immune cells, consider using a dual crosslinking approach with disuccinimidyl glutarate (DSG) before formaldehyde to better capture protein-protein interactions

• Chromatin shearing:

  • Optimize sonication to generate DNA fragments between 200-500 bp

  • Verify fragmentation efficiency by agarose gel electrophoresis before immunoprecipitation

  • For NFKB1 ChIP, more extensive sonication may be required as NF-κB factors often bind enhancer regions with complex chromatin structures

• Immunoprecipitation parameters:

  • Use 2-5 μg of NFKB1 (Ab-907) Antibody per ChIP reaction

  • Include appropriate controls: input chromatin (pre-immunoprecipitation sample), IgG control, and a positive control antibody (e.g., H3K4me3)

  • Incubate chromatin-antibody mixture overnight at 4°C with rotation

  • Include high salt wash steps (up to 500mM NaCl) to reduce non-specific binding

  • Consider sequential ChIP (Re-ChIP) to identify specific dimer configurations (p50 homodimers versus p50/RelA heterodimers)

• Data analysis considerations:

  • Design qPCR primers flanking known κB sites (consensus: 5'-GGRNNYYCC-3')

  • Include primer sets for negative control regions (no known κB sites)

  • For data normalization, calculate percent input or fold enrichment over IgG

  • Expect significant enrichment at NF-κB target genes after stimulation compared to unstimulated conditions

How can I distinguish between p50 homodimer-mediated gene repression and p50-p65 heterodimer-mediated gene activation?

Differentiating between p50 homodimer repression and p50-p65 heterodimer activation is crucial for understanding NF-κB functional outcomes. NFKB1 (Ab-907) Antibody can be applied in several strategic approaches:

• Sequential ChIP (Re-ChIP) analysis:

  • First immunoprecipitate with NFKB1 (Ab-907) to capture all p50-containing complexes

  • Split the sample and perform a second immunoprecipitation with either another NFKB1 antibody or an antibody against RelA/p65

  • p50 homodimers will be enriched in the NFKB1→NFKB1 Re-ChIP

  • p50-p65 heterodimers will be detected in the NFKB1→RelA Re-ChIP

  • This technique allows precise identification of dimer composition at specific genomic loci

• Co-factor recruitment profiling:

  • Repressive p50 homodimers typically associate with histone deacetylases (HDAC1, HDAC3)

  • Activating p50-p65 heterodimers recruit histone acetyltransferases (p300, CBP)

  • ChIP for p50 with NFKB1 (Ab-907) followed by analysis of co-factor recruitment helps distinguish complex types

  • Research also shows that Bcl-3 can associate with p50 homodimers, converting them from repressors to activators in specific contexts

• Gene expression correlation:

  • Integrate ChIP-seq data with RNA-seq analysis

  • Genes bound by p50 only (using Ab-907) with decreased expression likely represent p50 homodimer repression targets

  • Genes bound by both p50 and RelA with increased expression typically indicate heterodimer activation

  • Studies of NFKB1 mutant cells show dysregulation of numerous NF-κB target genes, reflecting the complex regulatory role of NFKB1-containing complexes

• Temporal analysis:

  • p50 homodimers often function in the resolution phase of inflammation

  • Track dimer composition changes over a time course of activation

  • In early phases, expect p50-p65 heterodimer predominance

  • Later phases often show increased p50 homodimer formation

  • This temporal regulation is frequently disrupted in inflammatory diseases associated with NFKB1 dysfunction

What are the key differences in sample preparation for detecting cytoplasmic p105 versus nuclear p50?

Accurate detection of cytoplasmic p105 versus nuclear p50 requires specialized sample preparation techniques due to their distinct subcellular localization and protein characteristics:

• Subcellular fractionation protocols:

  For cytoplasmic p105 extraction:

  • Use gentle lysis buffers containing low detergent concentrations (0.1% NP-40 or Triton X-100)

  • Include phosphatase inhibitors to maintain post-translational modifications

  • Add proteasome inhibitors (MG132) to prevent artifactual p105 processing during extraction

  • Perform brief centrifugation (600-1000g) to pellet nuclei while retaining cytoplasmic fraction

  • Keep samples cold throughout processing to minimize protein degradation

  For nuclear p50 extraction:

  • After cytoplasmic removal, wash nuclear pellet thoroughly to eliminate cytoplasmic contamination

  • Extract with high-salt buffer (typically 400-500mM NaCl) to efficiently release DNA-bound factors

  • Include DNase treatment to release tightly bound transcription factors

  • Consider sonication to disrupt nuclear membranes and improve extraction efficiency

  • Concentrate nuclear extracts if p50 signal is weak

• Verification of fraction purity:

  • Always confirm fraction purity by blotting for compartment-specific markers

  • Cytoplasmic markers: GAPDH, α-tubulin

  • Nuclear markers: Lamin B1, Histone H3

  • Cross-contamination can lead to misinterpretation of p105/p50 distribution

  • In properly prepared fractions, p105 should predominate in cytoplasmic extracts while p50 should be enriched in nuclear extracts during active signaling

• Special considerations for stimulated samples:

  • For studying NF-κB activation dynamics, prepare fractions at multiple timepoints after stimulation

  • Expect increased nuclear p50 following stimulation with TNFα, IL-1β, or LPS

  • In NFKB1 mutant cells, nuclear translocation of p50 may be significantly impaired

  • Compare subcellular distribution patterns between wild-type and mutant samples to assess signaling defects

How can I optimize western blot protocols with NFKB1 (Ab-907) Antibody to clearly distinguish p105 and p50?

Achieving clear separation and detection of p105 (105 kD) and p50 (50 kD) forms requires optimization of multiple western blot parameters:

• Gel electrophoresis optimization:

  • Use 8-10% acrylamide gels for optimal separation of proteins in this size range

  • Consider gradient gels (4-15%) for simultaneous detection of p105 and p50 with maximal separation

  • Extend electrophoresis time at moderate voltage (100-120V) to enhance band separation

  • Include precision protein markers with bands near 50 kD and 100 kD for accurate size determination

  • Load 20-50 μg total protein per lane, adjusting based on NFKB1 abundance in your samples

• Transfer considerations:

  • For simultaneously detecting both forms, wet transfer systems generally provide better results

  • Use PVDF membranes with 0.45 μm pore size for optimal protein retention

  • Transfer at 100V for 60-90 minutes in cold transfer buffer containing 10-15% methanol

  • After transfer, verify efficiency by reversible Ponceau S staining

  • For high molecular weight p105, extended transfer times may be necessary to ensure complete transfer

• Antibody incubation parameters:

  • Block membranes with 5% non-fat dry milk in TBS-T for 1 hour at room temperature

  • Dilute NFKB1 (Ab-907) Antibody 1:1000-1:2000 in 5% BSA in TBS-T

  • Incubate overnight at 4°C with gentle agitation for optimal binding

  • Wash extensively (5× for 5 minutes each) with TBS-T before secondary antibody incubation

  • Include positive controls from cell lines with known NFKB1 expression (e.g., activated B cells)

• Detection optimization:

  • Use enhanced chemiluminescence (ECL) with extended signal duration

  • Capture multiple exposure times to ensure both high and low abundance forms are visible without saturation

  • For precise quantification, consider fluorescent secondary antibodies and digital imaging

  • When analyzing samples from patients with NFKB1 mutations, expect significantly reduced band intensities for both p105 and p50 compared to controls

• Troubleshooting common issues:

  • Poor p105 detection: Extend transfer time, reduce gel percentage, check for proteolytic degradation

  • Weak p50 signal: Increase antibody concentration, extend incubation time, enhance detection reagent sensitivity

  • Multiple bands: Verify specificity with knockout controls, consider post-translational modifications or processing intermediates

  • High background: Increase blocking time, dilute antibody further, add additional wash steps

What factors might affect the binding efficiency of NFKB1 (Ab-907) Antibody in different experimental contexts?

Multiple factors can influence NFKB1 (Ab-907) Antibody binding efficiency across different experimental applications:

• Epitope accessibility considerations:

  • Protein conformation: The three-dimensional structure of NFKB1 differs between applications (native in IP/ChIP vs. denatured in western blot)

  • Post-translational modifications: Phosphorylation, ubiquitination, or acetylation near the epitope can mask antibody binding sites

  • Protein-protein interactions: NF-κB dimers and other interaction partners may sterically hinder epitope access

  • DNA binding: When p50 is bound to DNA at κB sites (consensus: 5'-GGRNNYYCC-3'), certain epitopes may become inaccessible

• Sample preparation effects:

  • Fixation impact: For immunohistochemistry/immunofluorescence, overfixation with formaldehyde can mask epitopes

  • Extraction methods: Different lysis buffers extract NFKB1 with varying efficiency

  • Denaturing conditions: Temperature and detergent concentration affect protein unfolding

  • Protease and phosphatase inhibitors: Their absence may lead to degradation or modification of the epitope

• Application-specific challenges:

  For western blotting:

  • Complete denaturation is crucial for consistent detection

  • Transfer efficiency affects detection of larger p105 form

  • Blocking reagents may influence antibody binding

  For immunoprecipitation:

  • Detergent concentration must balance solubilization with epitope preservation

  • Salt concentration affects antibody-antigen interaction strength

  • Pre-clearing of lysates reduces non-specific binding

  For ChIP applications:

  • Crosslinking conditions significantly impact epitope availability

  • Sonication parameters affect chromatin fragment size and epitope exposure

  • Washing stringency balances specific signal with background reduction

• Cell type and stimulation variables:

  • Basal expression levels vary dramatically between cell types (higher in immune cells)

  • Activation state alters NFKB1 localization, processing, and modifications

  • Stimulus-specific effects: Different NF-κB activators (TNFα, LPS, IL-1β) induce distinct modifications

  • Studies show that NFKB1 mutations significantly impair the response to these stimuli, providing valuable control samples

What are best practices for quantifying NFKB1 expression levels using NFKB1 (Ab-907) Antibody?

Accurate quantification of NFKB1 expression using Ab-907 requires rigorous methodology and appropriate controls:

• Western blot quantification approach:

  • Establish the linear dynamic range for detection of both p105 and p50 forms

  • Use appropriate loading controls: β-actin or GAPDH for total protein; HDAC1 or Lamin B1 for nuclear fractions

  • Capture multiple exposure times to ensure signal is within the linear range

  • Perform minimum three biological replicates for statistical validity

  • Calculate both absolute expression levels and the p105/p50 ratio, which reflects processing dynamics

  • For patients with NFKB1 mutations, significant reductions in both protein forms have been documented

• Densitometry best practices:

  • Use validated analysis software (ImageJ, Image Lab)

  • Implement consistent background subtraction methodology

  • Draw identical region of interest boundaries for comparable samples

  • Avoid analysis of saturated pixels, which invalidates quantification

  • Measure integrated density (area × mean intensity) rather than peak intensity

  • Normalize to loading controls before comparing between conditions

• Immunofluorescence quantification:

  • Perform cell-by-cell analysis rather than field-level measurements

  • Measure nuclear and cytoplasmic intensities separately in defined regions

  • Report distributions of values rather than simply means

  • Use automated image analysis algorithms to eliminate selection bias

  • Include colocalization analysis when studying interactions with other proteins

  • Research has shown significant differences in NF-κB component localization in cells from patients with NFKB1 mutations

• Flow cytometry considerations:

  • Optimize fixation and permeabilization for intracellular staining

  • Include appropriate isotype controls

  • Perform fluorescence-minus-one (FMO) controls

  • Report median fluorescence intensity rather than percent positive

  • Consider phospho-flow approaches to simultaneously measure activation status

  • Patient-derived cells with NFKB1 mutations may show altered expression patterns that can serve as biological controls

• Data reporting standards:

  • Include representative images with scale bars

  • Report both normalized values and raw data

  • Present error bars representing biological variation

  • Specify exact quantification methodology in materials and methods

  • Note antibody dilution, exposure time, and image acquisition parameters

  • Include statistical analysis appropriate for sample size and data distribution